Compare ADMA Biologics Inc (ADMA) vs Chewy Inc (CHWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Chewy Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Chewy Inc trades at $20.58 (market cap $8.49B). The key difference: Chewy Inc is far larger — about 4× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | CHWY | |
|---|---|---|
Market Cap | $2.13B | $8.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $42.33 |
52-Week Low | $7.60 | $17.51 |
Enterprise Value | $2.20B | $8.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Chewy (CHWY) trades at $20.73, down 0.58% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported $11.86B in revenue for 2025 with a net income margin of 1.99%, showing improved profitability from prior years. Recent news highlights market share gains through its Autoship program and expansion into pet healthcare services, though the stock faces pressure from lowered 2026 growth expectations.
The outlook remains positive with an 81.58% buy rating from analysts and a $34.92 consensus price target, suggesting significant upside. Key risks include competitive pressures in the pet care sector and execution challenges in integrating new veterinary services. Investors should weigh strong customer loyalty and recurring revenue streams against near-term volatility and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
